Welcome to the Working Group on New TB Drugs Blog
Winstone’s Voice
As has been widely reported, we lost Winstone Zulu, a tireless advocate for TB/HIV. Chief among his gifts was the ability to speak with passion about his subject, finding the precise balance between hard facts, personal history, and an inspiring call to action.
TB R&D Weekly Update: Potential Use of Polyether Ionophores Against TB
During this week’s TB R&D Weekly Update, we explore the potential of polyether ionophores as anti-tuberculosis agents in an article published in 2009 by Kevin, et al. Links to additional TB R&D News are included.
Posted in Action, Announcements, Events, TB News, TB Prevention and Control Strategies, TB Treatment
Call to Action–Save a million lives by 2015
On June 6, 2011, the Stop TB Partnership launched the initiative Time to Act–Save a Million Lives by 2015 at the UN Headquarters at a reception hosted by Ray Chambers, the UN Secretary-General’s Special Envoy for Malaria and UN MDG Advocate. If you would like to respond to this call to action, visit www.action.org.
Posted in TB Pediatrics, TB Treatment, Video, Voices from the Fight to Stop Tuberculosis
Interview with Dr. Mark Cotton – Part Two
Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years. This is part two of our interview with him.
Posted in TB Pediatrics, TB Treatment, Video, Voices from the Fight to Stop Tuberculosis
Interview with Dr. Mark Cotton – Part One
Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years.
TB R&D Weekly Update: Combined Isoniazid and Antiretroviral Therapy Protects HIV-infected Children
In this week’s TB R&D update, the focus is on pediatrics and tuberculosis with several studies published on the subject. Frigati, et al., wanted to determine if isoniazid preventive therapy (IPT) combine with antiretroviral therapy (ART) would reduce TB in HIV-infected children. The article is published online ahead of print this month in Thorax and is entitled “The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.” Also, links to additional news in TB R&D are included.
Posted in Announcements, Regulations and Guidelines, TB Prevention and Control Strategies, TB Treatment
New Report on Drugs for Drug-resistant TB
The Médecins Sans Frontières and The Union will release on World TB Day a new report entitled “DR-TB drugs under the microscope” outlining drugs currently available to treat drug-resistant tuberculosis (DR-TB) including product information, sources of the drug, quality status, and price.
TB R&D Weekly Update: Study of Mother-to-Child Transmission of HIV Shows TB to be Risk Factor
In this week’s TB R&D update, we look at TB as a risk factor for mother-to-child transmission of HIV. The research is published in the February issue of the Journal of Infectious Diseases and is entitled “Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus.” Also, links to additional news in TB R&D are included.
Interview with Dr. Anneke Hesseling – Part One
An interview with Dr. Anneke Hesseling, the Director of the Paediatric TB Research Program at the Desmond Tutu TB Centre at Stellenbosch University in Cape Town, South Africa.
World AIDS Day Recap: The WHO issues new guidelines for TB prevention for people with HIV
On World AIDS day, the WHO Department of HIV/AIDS and the Stop TB Department issued new guidelines showing how people with HIV can be protected from tuberculosis with regular and low-cost preventive medication.
-
Toppix TB News- Editorial: Lives at risk if the U.S. shortchanges Global Fund 4 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- WHO says TB in Russia displays highest known drug resistance 3 Feb 2012
- Media outlets examine Global Fund's future as it enters second decade 3 Feb 2012
